Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$43.52 USD
+0.67 (1.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $43.47 -0.05 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Avidity Biosciences, Inc. [RNA]
Reports for Purchase
Showing records 1 - 20 ( 62 total )
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Acquisition by BioMarin Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biomarin (BMRN-NC) to Acquire Prosensa for $17.75, Lowering to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Recent Competitor Setbacks May Not Have Much Bearing on NDA Submission
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Back in the Lead Again, Initiation of the Rolling NDA Submission
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Study Design Likely To Mimic Competitor''s
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Could Patient Re-Dosing Be the Rebirth of Drisapersen?
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Rethinking Exon Skipping and Upgrading Prosensa to Buy
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Avidity Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We initiate with a Neutral rating and a $12 price target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D